Effects of SGLT2 inhibitor (Suglat) on insulin sensitivity in patients with type 2 diabetes mellitus by the glucose clamp technique and the meal tolerance test.

Effects of SGLT2 inhibitor (Suglat) on insulin sensitivity in patients with type 2 diabetes mellitus by the glucose clamp technique and the meal tolerance test. - The insulin resistance improvement effect of SGLT2 inhibitor (Suglat) in type 2 diabetes mellitus.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014521

Enrollment

Registered

2014-07-09

Start date

2014-05-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

SGLT2 inhibitor (Suglat) dosage

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes mellitus patient.

Exclusion criteria

Exclusion criteria: Type 1 diabetes mellitus, pancreatic disease, liver disease, renal failure, or those taking diabetogenic medications such as corticosteroids

Design outcomes

Primary

Measure	Time frame
Improvement of glucose infusion rate during euglycemic-hyperinsulinemic clamp and improvement of HbA1c and postprandial blood glucose.	—

Countries

Japan

Contacts

Public ContactYouhei Fujioka

Tottori University Faculty of Medicine Division of Cardiovascular Medicine, Endocrinology and Metabolism

yohei_0201@ybb.ne.jp0859-38-6517

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026